Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mensospas
- Development stage
- Unknown
- Lead developer
- Anthus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mensospas is an oral combination tablet developed and marketed by Anthus Pharmaceuticals for the treatment of spasm-related pain and dysmenorrhea (menstrual cramps). The formulation contains three active ingredients: mefenamic acid (500mg), pamabrom (25mg), and dicyclomine hydrochloride (10mg). Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting prostaglandin synthesis. Dicyclomine hydrochloride is an antispasmodic agent that relieves smooth muscle spasms in the gastrointestinal and urogenital tracts by antagonizing muscarinic receptors. Pamabrom is a mild diuretic that helps alleviate water retention and bloating associated with menstruation. This multi-modal approach is designed to address the primary symptoms of dysmenorrhea, including pain, cramping, and bloating. The drug is approved and marketed in India as a prescription product.
- Brand names
- Mensospas
02
Targets
M1 (Muscarinic acetylcholine receptor M1)ADORA2A (Adenosine A₂A Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CHRM3 (M3)PGHS-1 (Prostaglandin G/H Synthase 1)ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on Mensospas.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mensospas.